PMC:7283670 / 84029-84872 9 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T729 | 0-93 | Sentence | denotes | Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: |
| T730 | 94-177 | Sentence | denotes | NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: |
| T731 | 178-188 | Sentence | denotes | NestCell®: |
| T732 | 189-343 | Sentence | denotes | All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days): |
| T733 | 344-394 | Sentence | denotes | Disappear time of ground‐glass shadow in the lungs |
| T734 | 395-405 | Sentence | denotes | Secondary: |
| T735 | 406-843 | Sentence | denotes | Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020 |